Xilio Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Xilio Therapeutics, Inc. filed a Form 8-K reporting an Item 5.02 event effective January 1, 2024. The filing concerns annual equity awards granted to executive officers under the company’s 2021 Stock Incentive Plan. The report was signed and filed on January 3, 2024.
Financial Metrics and Capitalization
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It also does not disclose the grant-date fair value or total accounting expense associated with the awards.
Material Changes Versus Prior Period
- René Russo, Pharm.D., chief executive officer, president, and principal executive officer, received 177,000 restricted stock units.
- Kevin Brennan, senior vice president of finance and accounting and principal financial and accounting officer, received 20,000 restricted stock units.
- Each award vests in four equal annual installments beginning January 1, 2025, subject to continued service through each applicable vesting date.
- The awards were granted under the 2021 Stock Incentive Plan and are governed by the related restricted stock unit agreement.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management commentary, contingencies, or business-risk updates. The principal disclosed consideration is potential future dilution and stock-based compensation expense associated with the restricted stock units, although the filing does not quantify either item.
Important Facts to Verify
- Confirm the applicable accounting grant-date fair value and expected stock-based compensation expense.
- Assess the potential dilution from the 197,000 restricted stock units, subject to vesting and continued service.
- Review the Form of Restricted Stock Unit Agreement filed as Exhibit 10.1 for detailed vesting, forfeiture, and other award terms.
- Consult the company’s subsequent periodic filings for the effect of these awards on share-based compensation, outstanding shares, and liquidity.